281 related articles for article (PubMed ID: 22792508)
1. Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies.
Mavragani CP; Spyridakis EG; Koutsilieris M
Int J Inflam; 2012; 2012():879020. PubMed ID: 22792508
[TBL] [Abstract][Full Text] [Related]
2. Adult-onset Still's disease-pathogenesis, clinical manifestations, and new treatment options.
Kadavath S; Efthimiou P
Ann Med; 2015 Feb; 47(1):6-14. PubMed ID: 25613167
[TBL] [Abstract][Full Text] [Related]
3. Adult-Onset Still's Disease: Molecular Pathophysiology and Therapeutic Advances.
Sfriso P; Bindoli S; Galozzi P
Drugs; 2018 Aug; 78(12):1187-1195. PubMed ID: 30069732
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis and management of adult-onset Still's disease.
Efthimiou P; Georgy S
Semin Arthritis Rheum; 2006 Dec; 36(3):144-52. PubMed ID: 16949136
[TBL] [Abstract][Full Text] [Related]
5. Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies.
Efthimiou P; Kontzias A; Hur P; Rodha K; Ramakrishna GS; Nakasato P
Semin Arthritis Rheum; 2021 Aug; 51(4):858-874. PubMed ID: 34175791
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-37 is increased in adult-onset Still's disease and associated with disease activity.
Chi H; Liu D; Sun Y; Hu Q; Liu H; Cheng X; Ye J; Shi H; Yin Y; Liu M; Wu X; Zhou Z; Teng J; Yang C; Su Y
Arthritis Res Ther; 2018 Mar; 20(1):54. PubMed ID: 29566725
[TBL] [Abstract][Full Text] [Related]
7. AIM2 and NLRC4-driven inflammasome activation in adult-onset Still's disease and the preliminary therapeutic effect exploration of carboxyamidotriazole.
Duan M; Shen M; Zhou Y; He Y; Guo Z; Ye C; Li J; Zhu L
Clin Rheumatol; 2023 Jun; 42(6):1635-1643. PubMed ID: 36418508
[TBL] [Abstract][Full Text] [Related]
8. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease.
Chen DY; Lan JL; Lin FJ; Hsieh TY
J Rheumatol; 2004 Nov; 31(11):2189-98. PubMed ID: 15517632
[TBL] [Abstract][Full Text] [Related]
9. Adult-onset Still's disease: Advances in the treatment.
Castañeda S; Blanco R; González-Gay MA
Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):222-238. PubMed ID: 27886796
[TBL] [Abstract][Full Text] [Related]
10. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?
Efthimiou P; Kontzias A; Ward CM; Ogden NS
Nat Clin Pract Rheumatol; 2007 Jun; 3(6):328-35. PubMed ID: 17538564
[TBL] [Abstract][Full Text] [Related]
11. Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions.
Maria AT; Le Quellec A; Jorgensen C; Touitou I; Rivière S; Guilpain P
Autoimmun Rev; 2014 Nov; 13(11):1149-59. PubMed ID: 25183244
[TBL] [Abstract][Full Text] [Related]
12. Development and Role in Therapy of Canakinumab in Adult-Onset Still's Disease.
Galozzi P; Baggio C; Bindoli S; Oliviero F; Sfriso P
Front Pharmacol; 2018; 9():1074. PubMed ID: 30298010
[TBL] [Abstract][Full Text] [Related]
13. Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still's Disease.
Li S; Zheng S; Tang S; Pan Y; Zhang S; Fang H; Qiao J
Clin Rev Allergy Immunol; 2020 Feb; 58(1):71-81. PubMed ID: 31147820
[TBL] [Abstract][Full Text] [Related]
14. Adult-Onset Still's Disease: Novel Biomarkers of Specific Subsets, Disease Activity, and Relapsing Forms.
Maranini B; Ciancio G; Govoni M
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948117
[TBL] [Abstract][Full Text] [Related]
15. Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.
Colafrancesco S; Manara M; Bortoluzzi A; Serban T; Bianchi G; Cantarini L; Ciccia F; Dagna L; Govoni M; Montecucco C; Priori R; Ravelli A; Sfriso P; Sinigaglia L;
Arthritis Res Ther; 2019 Dec; 21(1):275. PubMed ID: 31829244
[TBL] [Abstract][Full Text] [Related]
16. Differences and similarities in cytokine profiles of macrophage activation syndrome in systemic lupus erythematosus and adult-onset Still's disease.
Hiyama T; Kurasawa K; Hasegawa A; Miyao T; Tanaka A; Arai S; Arima M; Maezawa R
Clin Exp Med; 2023 Nov; 23(7):3407-3416. PubMed ID: 36611087
[TBL] [Abstract][Full Text] [Related]
17. Serum Interleukin-18 Provides a Clue to the Diagnosis of Adult-Onset Still's Disease: Findings from 6 Japanese Patients with Adult-Onset Still's Disease.
Ogita A; Ansai SI; Saeki H
J Nippon Med Sch; 2022 Mar; 89(1):114-118. PubMed ID: 34526450
[TBL] [Abstract][Full Text] [Related]
18. Biologic treatments for adult-onset Still's disease.
Al-Homood IA
Rheumatology (Oxford); 2014 Jan; 53(1):32-8. PubMed ID: 23864171
[TBL] [Abstract][Full Text] [Related]
19. Elevated plasma galectin-3 levels and their correlation with disease activity in adult-onset Still's disease.
Chen PK; Lan JL; Li JP; Chang CK; Chang SH; Huang PH; Yeo KJ; Chen DY
Clin Rheumatol; 2020 Jun; 39(6):1945-1952. PubMed ID: 31960208
[TBL] [Abstract][Full Text] [Related]
20. Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still's disease.
Hu Q; Shi H; Zeng T; Liu H; Su Y; Cheng X; Ye J; Yin Y; Liu M; Zheng H; Wu X; Chi H; Zhou Z; Jia J; Sun Y; Teng J; Yang C
Arthritis Res Ther; 2019 Jan; 21(1):9. PubMed ID: 30616678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
